PT-141 10mg/vial 1 Vial by Master Pharma

Usage

1. Remove the lyophilised PT-141 vial from refrigeration 5 minutes before use; do not allow it to warm beyond room temperature before reconstitution.
2. Draw 2ml of bacteriostatic water into a standard insulin syringe and inject it slowly down the interior wall of the vial — never directly onto the powder cake.
3. Swirl the vial gently in a circular motion until the powder is fully dissolved; the solution should be clear and colourless. Discard if particulate matter or cloudiness is present.
4. Calculate your required dose volume (e.g. 1.75mg = 0.35ml from a 2ml-reconstituted 10mg vial) and draw the correct volume into a fresh 29–31g insulin syringe.
5. Select an injection site — lower abdomen 2cm from the navel or lateral thigh — pinch a skin fold, insert at 45°, and inject slowly into the subcutaneous fat layer.
6. After injection, store the reconstituted vial upright at 2–8 °C protected from light; label with the reconstitution date and discard after 28 days.

Warnings

Frequently asked questions

What is the correct diluent for reconstituting PT-141 10mg peptide vials?

Bacteriostatic water (0.9% benzyl alcohol) is the recommended diluent for PT-141 reconstitution. It extends the in-use shelf life of the reconstituted solution to approximately 28 days at 2–8 °C, compared to roughly 72 hours with plain sterile water. Add the diluent slowly down the vial wall and swirl gently — never shake or vortex — to preserve peptide chain integrity.

How do you calculate the PT-141 dose per syringe after reconstituting a 10mg vial?

Add 2ml of bacteriostatic water to the 10mg vial; each 0.2ml drawn with a U-100 insulin syringe equals 1mg of Bremelanotide. For a 1.75mg starting dose, draw 0.35ml. This ratio is consistent with HPLC-confirmed fill weights and allows precise insulin-syringe dosing without conversion errors.

How long can a reconstituted PT-141 vial be stored in the refrigerator?

A PT-141 vial reconstituted with bacteriostatic water should be stored upright at 2–8 °C, protected from light, and used within 28 days. After this window, residual benzyl alcohol preservative efficacy declines and microbial contamination risk rises. Discard any remaining solution after 28 days even if the vial is not empty.

Which injection technique is correct for administering PT-141 subcutaneously?

Use a 29–31 gauge, 8mm insulin syringe. Pinch a fold of abdominal or lateral-thigh skin, insert the needle at a 45° angle into the subcutaneous fat layer, and inject slowly. Rotate sites with each dose to prevent localised tissue irritation or lipodystrophy. Administer 45–60 minutes before the desired window of effect to match PT-141's pharmacokinetic onset profile.

Does PT-141 lyophilised powder need refrigeration before reconstitution?

Yes. Unreconstituted lyophilised PT-141 vials should be stored at 2–8 °C and never frozen; freeze-thaw cycling damages the peptide's amorphous matrix produced during lyophilisation. Master Pharma's GMP-validated freeze-drying cycle targets residual moisture below 1% w/w, a specification confirmed by Karl Fischer titration — but that stability depends on maintaining the cold chain throughout storage. (2) angle_used

Manufacturer

Dosing accuracy for peptide SKUs presents a specific manufacturing challenge: the fill weight of a lyophilised vial and the concentration declared on the label must correspond precisely, because the end-user's entire dose calculation depends on that correspondence. Master Pharma addresses this through gravimetric fill verification at the point of vial closure — each vial in a PT-141 batch is weighed before and after filling, with individual fill weights recorded against a tolerance specification of ±2% of the nominal 10mg target. Vials falling outside that window are segregated and rejected before lyophilisation begins, not after. The lyophilised cake's mass consistency is then cross-referenced against the in-process HPLC potency assay run on pre-lyophilisation bulk solution, creating a two-point verification: one gravimetric, one chromatographic. This dual-check architecture means the concentration printed on the Master Pharma PT-141 vial label reflects a measured quantity, not a theoretical one derived from formulation intent alone.